LAKE FOREST, Ill., March 4, 2014 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that David J. Endicott has been named ...
Fitch Ratings has affirmed France-based healthcare company Sanofi SA's (Sanofi) Long-term Issuer Default Rating (IDR) and senior unsecured rating at 'AA-' and its Short-term IDR at 'F1+. The affirmation reflects Sanofi's ability to weather the US patent expiry of Plavix (expired May 2012) and Avapro (expired March 2012), excellent market positions in the global pharmaceuticals, vaccines and animal healthcare markets, its well-placed late stage R&D pipeline, strong financial profile as well as its broad product range and strong geographical diversification. These positives are partly offset by the future patent expiry of its top selling drug Lantus (in 2015) and the number of setbacks the company has faced in its late stage pipeline in 2013. Sanofi retains ample financial flexibility.
Biosimilar drugs market
TheStreet highlights 3 stocks pushing the drugs industry lower today.
Hospira's fourth quarter 2013 adjusted earnings of 51 cents per share surpassed the Zacks Consensus Estimate by a penny.
F. Michael Ball Thank you, Karen and good morning everyone. Welcome to our fourth quarter and full year 2013 conference call.